These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24615483)
1. Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway. Mencej-Bedrač S; Zupan J; Mlakar SJ; Zavratnik A; Preželj J; Marc J Drug Metabol Drug Interact; 2014; 29(2):111-4. PubMed ID: 24615483 [TBL] [Abstract][Full Text] [Related]
2. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women. Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533 [TBL] [Abstract][Full Text] [Related]
3. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. Mencej-Bedrac S; Prezelj J; Kocjan T; Teskac K; Ostanek B; Smelcer M; Marc J J Mol Endocrinol; 2009 Mar; 42(3):239-47. PubMed ID: 19131500 [TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women. Tu P; Duan P; Zhang RS; Xu DB; Wang Y; Wu HP; Liu YH; Si L Osteoporos Int; 2015 Jan; 26(1):179-85. PubMed ID: 25138264 [TBL] [Abstract][Full Text] [Related]
5. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM Menopause; 2007; 14(5):913-8. PubMed ID: 17667143 [TBL] [Abstract][Full Text] [Related]
6. Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. Mencej S; Prezelj J; Kocijancic A; Ostanek B; Marc J Maturitas; 2006 Oct; 55(3):219-26. PubMed ID: 16730419 [TBL] [Abstract][Full Text] [Related]
7. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483 [TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis. Mencej S; Albagha OM; Prezelj J; Kocjan T; Marc J J Mol Endocrinol; 2008 Jun; 40(6):273-9. PubMed ID: 18502820 [TBL] [Abstract][Full Text] [Related]
9. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia. Zheng H; Wang C; He JW; Fu WZ; Zhang ZL Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211 [TBL] [Abstract][Full Text] [Related]
10. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women. Mencej-Bedrač S; Preželj J; Marc J Maturitas; 2011 Jul; 69(3):263-7. PubMed ID: 21411255 [TBL] [Abstract][Full Text] [Related]
11. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women. Shang M; Lin L; Cui H Clin Biochem; 2013 Oct; 46(15):1493-501. PubMed ID: 23531404 [TBL] [Abstract][Full Text] [Related]
12. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women. Markatseli AE; Hatzi E; Bouba I; Georgiou I; Challa A; Tigas S; Tsatsoulis A Maturitas; 2011 Oct; 70(2):188-93. PubMed ID: 21840657 [TBL] [Abstract][Full Text] [Related]
13. The RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosis. Wolski H; Drews K; Bogacz A; Kamiński A; Barlik M; Bartkowiak-Wieczorek J; Klejewski A; Ożarowski M; Majchrzycki M; Seremak-Mrozikiewicz A Ginekol Pol; 2016; 87(5):347-52. PubMed ID: 27304650 [TBL] [Abstract][Full Text] [Related]
14. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479 [TBL] [Abstract][Full Text] [Related]
15. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z Menopause; 2009; 16(5):950-5. PubMed ID: 19387415 [TBL] [Abstract][Full Text] [Related]
16. Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women. Kim H; Choe SA; Ku SY; Kim SH; Kim JG Menopause; 2011 Jul; 18(7):808-13. PubMed ID: 21471826 [TBL] [Abstract][Full Text] [Related]
17. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. Roshandel D; Holliday KL; Pye SR; Boonen S; Borghs H; Vanderschueren D; Huhtaniemi IT; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC; Thomson W; O'Neill TW; J Bone Miner Res; 2010 Aug; 25(8):1830-8. PubMed ID: 20205168 [TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. Choi JY; Shin A; Park SK; Chung HW; Cho SI; Shin CS; Kim H; Lee KM; Lee KH; Kang C; Cho DY; Kang D Calcif Tissue Int; 2005 Sep; 77(3):152-9. PubMed ID: 16151677 [TBL] [Abstract][Full Text] [Related]